Prime Medicine 2025 net loss widens, hurt by higher R&D expenses

Prime Medicine

03/03/2026 13:12

Overview

Biotechnology firm reported net loss of $201.1 mln for 2025, slightly up from 2024

Company's cash position decreased to $191 mln as of December 31, 2025

Plans to file IND and CTA for Wilson Disease and AATD programs in 2026

Outlook

Prime Medicine plans IND/CTA submissions for Wilson Disease and AATD in 2026

Company expects initial clinical data for Wilson Disease and AATD programs in 2027

Prime Medicine anticipates cash runway into 2027

Result Drivers

HIGHER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses were $160.6 million for the year ended December 31, 2025, as compared to $155.3 million for the year ended December 31, 2024.

HIGHER GENERAL AND ADMINISTRATIVE (G&A) EXPENSES: G&A expenses were $52.3 million for the year ended December 31, 2025, as compared to $50.2 million for the year ended December 31, 2024.

Company press release: ID:nGNX2dGbRh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.35
FY Net Income
-$201.14 mln
FY Income from Operations
-$208.35 mln
FY Operating Expenses
$212.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Prime Medicine Inc is $6.00, about 28.8% above its March 2 closing price of $4.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)